Scarica l'app Stockscreener
6.04
2.55%
0.15
Dopo l'orario di chiusura:
5.91
-0.13
-2.15%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SCLX Giù?
Forum
Previsione
Precedente Chiudi:
$5.89
Aprire:
$5.81
Volume 24 ore:
60,180
Relative Volume:
0.47
Capitalizzazione di mercato:
$33.12M
Reddito:
$46.74M
Utile/perdita netta:
$-114.33M
Rapporto P/E:
-4.6822
EPS:
-1.29
Flusso di cassa netto:
$-21.04M
1 W Prestazione:
+9.82%
1M Prestazione:
+17.97%
6M Prestazione:
-59.53%
1 anno Prestazione:
-90.82%
Intervallo 1D:
$5.72
$6.3318
Intervallo di 1 settimana:
$5.16
$6.4718
Portata 52W:
$3.60
$78.05
Scilex Holding Company Stock (SCLX) Company Profile
Nome
Scilex Holding Company
Settore
Industria
Telefono
(650) 516-4310
Indirizzo
960 SAN ANTONIO ROAD, PALO ALTO
Confronta SCLX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SCLX
Scilex Holding Company
|
6.04 | 33.12M | 46.74M | -114.33M | -21.04M | -1.29 |
|
LLY
Lilly Eli Co
|
775.90 | 724.64B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
155.92 | 376.43B | 89.33B | 21.81B | 18.57B | 8.99 |
|
NVO
Novo Nordisk Adr
|
69.82 | 352.49B | 43.59B | 15.04B | 10.74B | 3.3766 |
|
ABBV
Abbvie Inc
|
189.99 | 334.73B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
123.10 | 234.21B | 53.22B | 12.86B | 14.85B | 6.39 |
Scilex Holding Company Stock (SCLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-27 | Iniziato | D. Boral Capital | Buy |
| 2024-10-16 | Iniziato | Alliance Global Partners | Buy |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-10-16 | Iniziato | B. Riley Securities | Buy |
| 2023-10-13 | Iniziato | B. Riley Securities | Buy |
| 2023-10-09 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Scilex Holding Company Borsa (SCLX) Ultime notizie
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination - The Manila Times
Scilex reports publication on Gloperba dosing adjustments - TipRanks
Scilex Holding Company Announces Publication on GLOPERBA® Dosing Adjustments in Peer-Review Journal - The Manila Times
Scilex Postpones Annual Meeting Due to Quorum Issue - TipRanks
Scilex (NASDAQ:SCLX) Stock Price Down 2.8% – What’s Next? - Defense World
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - The Manila Times
Scilex Holding Company Presented Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional Pain Physicians (ASIPP), May 15-17, 2025 in Orlando, FL - GlobeNewswire Inc.
Scilex Bio signs binding term sheet with NeuroBiogen - TipRanks
Scilex Updates Director Compensation Following Stock Split - TipRanks
Scilex adjusts director compensation post-stock split - Investing.com
Scilex (SCLX) Expected to Announce Quarterly Earnings on Monday - Defense World
Scilex Holding Company to Present Post-Hoc Analysis of the C.L.E.A.R. Trial on Clinical Meaningfulness of Safety and Efficacy of SP-102 for the Treatment of Lumbosacral Radicular Pain (LRP) at the 27th Annual Meeting of American Society of Interventional - GlobeNewswire
Scilex Regains Compliance With Nasdaq Listing Rule; Shares Rise - marketscreener.com
Scilex Holding Company Regains Compliance with Nasdaq Minimum Closing Bid Price Requirement - Nasdaq
Scilex Holding Company Regains Compliance with NASDAQ Minimum Bid Price Rule - GlobeNewswire
Scilex Holding Company’s Market Journey: Closing Weak at 0.24, Down -2.01 - DWinneX
Scilex Adjusts Record Date for Preferred Stock Dividend - TipRanks
Scilex Holding Company Announces New Record Date for Preferred Stock Dividend - Nasdaq
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex's Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - The Manila Times
Scilex Holding Company Announces Change in Record Date for - GlobeNewswire
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of Scilex’s Ownership Interest in Semnur Pharmaceuticals, Inc., its Wholly Owned Subsidiary from April 11, 202 - Yahoo Finance
Scilex Holding Amends Merger Agreement with Denali By Investing.com - Investing.com Canada
Scilex Holding Amends Merger Agreement with Denali - Investing.com Australia
SCLX stock touches 52-week low at $5.8 amid market challenges - Investing.com
Scilex Holding Company announces completion of commercial manufacturing of Gloperba® with the brand marketed and distributed under Scilex Pharmaceuticals, Inc. and is expecting to Launch in the U.S. in the first quarter of 2024 - Seeking Alpha
Scilex Holding Company Announces FDA Has Approved Our Request for the Orphan Drug Designation for Colchicine for the Treatment of Pericarditis - The Manila Times
Scilex Gets FDA Orphan Drug Label for Colchicine for Pericarditis - marketscreener.com
Scilex Gets Orphan Drug Designation for Its Version of Colchicine - marketscreener.com
Scilex Holding Company Announces FDA Has Approved Our - GlobeNewswire
[Reporter’s Notebook] Is NeuroBiogen’s tisolagiline really worth $4.5 billion? - koreabiomed.com
Scilex Holding announces 1-for-35 reverse stock split By Investing.com - Investing.com Canada
What Does the Market Think About Scilex Holding?Scilex Holding (NASDAQ:SCLX) - Benzinga
Scilex Holding announces 1-for-35 reverse stock split - Investing.com Australia
Canada approves Scilex’s migraine solution ELYXYB - Investing.com
Scilex Holding Company Announces Approval of a New Drug - GlobeNewswire
Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada’s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB®’s Acute Treatment of Migraine With or Witho - Yahoo Finance
Scilex’s (SCLX) Hold Rating Reiterated at D. Boral Capital - Defense World
Scilex downgraded to Hold from Buy at D. Boral Capital - Yahoo Finance
Scilex announces 1-for-35 reverse stock split to meet Nasdaq rules - Investing.com Nigeria
Scilex to Implement 1-for-35 Reverse Stock Split - marketscreener.com
Scilex Announces Reverse Stock Split to Meet Nasdaq Rules - TipRanks
Scilex Holding Company Announces 1-For-35 Reverse Stock Split - marketscreener.com
Scilex Holding Company Announces 1-for-35 Reverse Stock Split - GlobeNewswire
Scilex (SCLX) Downgraded to Hold Following Reverse Stock Split Announcement | SCLX Stock News - GuruFocus
D. Boral Capital Cuts Scilex (NASDAQ:SCLX) Price Target to $18.00 - The AM Reporter
D. Boral Capital Has Lowered Expectations for Scilex (NASDAQ:SCLX) Stock Price - Defense World
Is Scilex Holding Company (NASDAQ: SCLX) Still A Good Investment? - stocksregister.com
Scilex Holding Company (SCLX) reports earnings - qz.com
Scilex (NASDAQ:SCLX) Stock Price Up 1.8% – Here’s What Happened - Defense World
Scilex Holding Company Has Appealed Lower Court Decision to - GlobeNewswire
Scilex Holding Company Has Appealed Lower Court Decision to the U.S. Court of Appeals for the Federal Circuit in Washington, DC and Will Continue to Vigorously Pursue its Infringement Action Against Aveva - The Manila Times
Scilex Holding Company Azioni (SCLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Scilex Holding Company Azioni (SCLX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Ji Henry | Executive Chairperson |
Oct 31 '24 |
Buy |
0.94 |
8,888 |
8,351 |
320,161 |
| SHAH JAISIM | See Remarks |
Oct 29 '24 |
Buy |
0.99 |
32,000 |
31,670 |
109,333 |
| Followwill Dorman | Director |
Oct 18 '24 |
Buy |
0.99 |
1,000 |
990 |
2,300 |
| Chun Jay | Director |
Oct 18 '24 |
Buy |
0.95 |
5,000 |
4,750 |
112,500 |
| Wu Yue Alexander | Director |
Oct 17 '24 |
Buy |
0.95 |
20,000 |
18,992 |
25,000 |
| Lemus David | Director |
Oct 17 '24 |
Buy |
0.90 |
2,000 |
1,800 |
2,000 |
| Ji Henry | Executive Chairperson |
Oct 17 '24 |
Buy |
0.97 |
10,000 |
9,710 |
60,070 |
| SHAH JAISIM | See Remarks |
Oct 16 '24 |
Buy |
0.99 |
30,000 |
29,751 |
77,333 |
| Ma Stephen Hoi | Chief Financial Officer |
Oct 16 '24 |
Buy |
0.97 |
6,700 |
6,499 |
22,840 |
1.53%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):